Prime Medicine (PRME) Receivables (2024 - 2025)
Prime Medicine (PRME) posted Receivables of $4.6 million for Q4 2025, up 3721.67% on a QoQ basis from $120000.0 in Q2 2025, and up 185.02% year-over-year from $1.6 million in Q4 2024.
Prime Medicine (PRME) Receivables (2024 - 2025) Analysis & Trends
Prime Medicine's Receivables history runs 2 years deep, the most recent figure standing at $4.6 million for Q4 2025.
- Quarterly Receivables rose 185.02% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 185.02% YoY) and the FY2025 annual result came in at $4.6 million, up 185.02% from the prior year.
- Receivables was $4.6 million for Q4 2025 at Prime Medicine, up from $120000.0 in the prior quarter.
- Across five years, Receivables topped out at $55.0 million in Q3 2024 and bottomed at $17000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Prime Medicine | 525.98 Mn | 525.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.59 Mn |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 55.00 Mn |